4 ms·
Exactly. This is what I was hoping for from an investigative piece on Theranos. Even an n=1 sample where the author had his or her blood tests done with Therano
by sowhatquestion 11y ago
Exactly. This is what I was hoping for from an investigative piece on Theranos. Even an n=1 sample where the author had his or her blood tests done with Theranos and a competitor would be worth more than all the speculation in this article.
- jacquesm 11y agoEspecially if such a test gave different results than the accepted competitors test.
- sobkas 11y agoBut they would have to spend money on tests, wait for them to finish and there might be a possibility tests won't show what they hoped for(even if their hypothesis is true). While speculation is cheap, fast and always trueish enough to warrant an article.
- jacquesm 11y agoYou mean they to hope that the tests would work as advertised? After all we're all in it for the best of the patient and a decrease in healthcare costs or an increase in quality for the same price, right?
- streptomycin 11y agoI don't think an n=1 test would be useful. Depending on people's preconceived biases, they would just say "see this confirms what I thought!" or "lol n=1 is meaningless". To do something conclusive, you'd need to do a real trial with n>>1. That costs way more money than Business Insider (or most other venues) is going to spend on an article.